Difference between revisions of "Event:1042"
From AOP-Wiki
(thomashill3 updated summary tables from widget page.) |
(thomashill3 updated summary tables from widget page.) |
||
Line 18: | Line 18: | ||
!Event Type | !Event Type | ||
!Essentiality | !Essentiality | ||
+ | |||
+ | |- | ||
+ | |||
+ | |[[Aop:164|Beta-2 adrenergic agonist activity leading to mesovarian leiomyomas in the rat and mouse]]||KE||[[Aop:164#Essentiality of the Key Events|Strong]] | ||
|- | |- |
Latest revision as of 19:43, 25 July 2016
Contents
Event Title
smooth muscle, Proliferation/Clonal Expansion
Key Event Overview
Please follow link to widget page to edit this section.
If you manually enter text in this section, it will get automatically altered or deleted in subsequent edits using the widgets.
AOPs Including This Key Event
AOP Name | Event Type | Essentiality |
---|---|---|
Beta-2 adrenergic agonist activity leading to mesovarian leiomyomas in the rat and mouse | KE | Strong |
Taxonomic Applicability
Name | Scientific Name | Evidence | Links |
---|
Level of Biological Organization
Biological Organization |
---|
How this Key Event works
How it is Measured or Detected
Methods that have been previously reviewed and approved by a recognized authority should be included in the Overview section above. All other methods, including those well established in the published literature, should be described here. Consider the following criteria when describing each method: 1. Is the assay fit for purpose? 2. Is the assay directly or indirectly (i.e. a surrogate) related to a key event relevant to the final adverse effect in question? 3. Is the assay repeatable? 4. Is the assay reproducible?